Hospital association contests Ball State monopoly study
The Indiana Hospital Association is disputing a Ball State University study of Hoosier hospitals that blames part of the high cost of health care on monopolies.
The Indiana Hospital Association is disputing a Ball State University study of Hoosier hospitals that blames part of the high cost of health care on monopolies.
The merger, announced Wednesday, is designed to give patients a more comprehensive approach to addiction and behavioral health services,” including treatment for serious mental illness and a psychiatric intensive care unit.
Announcement of the tech giant’s arrangement with Ascension followed reports that Google had access to thousands of patient health records without doctors’ knowledge.
Indiana had a higher percentage of people lacking medical insurance than any neighboring state in 2018, but its rate was better than the national average.
Underage vaping has reached what health officials call epidemic levels. In the latest government survey, 1 in 4 high school students reported using e-cigarettes in the previous month, despite federal law banning sales to those under 18.
Patient data is increasingly in the hands of for-profit industries. Insurance firms and other for-profit companies have been collecting patient data that yields important information that could be used to shape medical care and health policy.
The hospital system’s 45-year-old campus will likely need hundreds of millions of dollars in upgrades in coming years to keep it competitive long term.
Presidential candidate Elizabeth Warren’s plan is built on transferring to the government 98% of the $8.8 trillion she estimates that employers will spend on private insurance for their employees.
Starting in July, Indiana began requiring people to work, volunteer or participate in other qualifying activities as a condition for receiving medical benefits under the Healthy Indiana Plan, the state’s biggest Medicaid program.
By the end of the year, Recovery Force plans to seek FDA clearance for the system for hospitals that helps patients regain mobility. Sales could begin in mid-2020.
Abbott Laboratories announced plans Monday night to build a 120,000-square-foot facility in the NorthPoint Industrial Park along U.S. 31 where it will manufacture a heart valve repair device.
The company said Monday that it will close 150 Walgreens-run clinics by the end of the year, but it will keep open more than 200 that are run in partnership with health care providers.
Dr. Ulrich Klopfer competed so avidly in the 1970s to perform the most abortions each day that it was said he would set his coffee aside, jump to his feet in the break room and rush to the operating table whenever his chief rival in the macabre derby walked by.
Indianapolis orthodontist Jeff Biggs has been putting smiles on people’s faces for two decades. Now he’s hoping to put smiles on the faces of orthodontists themselves with a new one-stop online marketplace to launch early next month.
Digging through old data to salvage a seemingly failed Alzheimer’s drug paid off big time for Biogen Inc., but at least one of its rivals has no plans to follow suit.
Dr. Paul Wallach, an executive associate dean at Indiana University School of Medicine in Indianapolis, predicts that within the next decade, hand-held ultrasound devices will replace the stethoscope as part of the routine physical exam.
President Donald Trump and House Speaker Nancy Pelosi could hardly be more at odds—but behind the scenes, they’re still grasping at a bipartisan deal to lower the cost of prescription drugs.
Eli Lilly and Co. easily topped earnings expectations in the third quarter, but shares in the Indianapolis-based drug company tumbled nearly 5 percent Wednesday morning.
The Indianapolis-based insurer raised its 2019 forecast after attracting more customers covered by Medicare Advantage and Medicaid.
Seven months after clinical trials for a promising Alzheimer’s drug were halted and the treatment was declared a failure, a new analysis suggests it was actually effective, and the company that makes it plans to move forward in securing federal approval.